sector rotation into biotechs for 100%

As I have said I believe many bitotechs are tradig at less than half their base value let alone any possible price if a glimmer of optimism comes into the market.

So I am putting up a list of the main ones I watch and categorising them so punters here can argue over wether they are turning or no and add their own.

Bio's that are running or have turned/look strong -

PXS , BTA , PSX , CCE , SPL

Bio's that are turning , have flatlined for a turn or have news about to drop -

PSD ,CXS , PEP , EQX , AVX , AML , IMU , PRR , AGX , SBP, ACR

Bio's with no sign of change or are too hard to call -

ANP , MBP , PTD , ALT , PBO , CMQ , EPT

My favorites are PRR , AML & AGX for various reasons but closely followed by BTA , CCE & ACR.

AML is the safer pick with $50m in cash and a milestone paying deal with Merck , AGX is cash poor now but progressing with TBV Phase II (recently valued at $1.15 per share v 44c for the whole company) and PRR is cashed up & has changed management to chairman with M&A experience plus the have 3 new largest shareholders (2 are biotech specialists) and the have multiple technologies (with 100 patents or prosectuted patents) and multiple deals with overseas bio or big pharma. Also just had a research report from Southern Cross Equities valuing the at a base case 33c and optimistic case 88c - not bad for a 12c stock.

What's your favorites? Have I put names in the wrong category? TA specialists - I love you all but this is 90% FA argument so you will no doubt put most in the last category - consider that a given and save yourself the time replying.